Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?Zacks Investment Research • 03/09/23
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic typesGlobeNewsWire • 03/07/23
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023GlobeNewsWire • 02/01/23
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific InnovationGlobeNewsWire • 01/04/23
Certara Announces the Completion of Arsenal Capital Partners' Investment and the Appointment of David Spaight to the Board of DirectorsGlobeNewsWire • 12/08/22
Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock PurchaseGlobeNewsWire • 11/07/22
Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Software for Evaluating Regulatory SubmissionsGlobeNewsWire • 10/19/22
Certara, Inc. (CERT) CEO William Feehery on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22